| abstract |
Method of in-vitro diagnosis of Alzheimer's disease by means of a monoclonal antibody. Said antibody is capable of binding to at least the amino acids 12-16 of β-amyloid peptide, specifically detecting the neuritic plaques that are characteristic of Alzheimer's disease, without detecting diffuse plaques, which are not indicators of the disease, Among the neuritic plaques, the monoclonal antibody makes it possible to detect a subgroup that differs in the composition of the various isoforms of β-amyloid peptide that are deposited, which is associated with the stage of progression of the disease. Moreover, the antibody is capable of binding to isoforms of β-amyloid peptide in biological fluids such as urine. Accordingly, the monoclonal antibody of the invention, the cell lines which produce it and the compositions containing it can be used in the in-vitro diagnosis of Alzheimer's disease and determination of the stage of progression of the disease, |